

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



萬隆控股集團有限公司
Ban Loong Holdings Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 30)

VOLUNTARY ANNOUNCEMENT – BUSINESS UPDATE

This is a voluntary announcement made by Ban Loong Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”). The board (the “**Board**”) of directors (the “**Directors**”) of the Company would like to provide on a voluntary basis to keep the shareholders and potential investors of the Company informed of the status of the latest development.

The Board is pleased to announce that on 30 May 2022 (after trading hours), the Company entered into a strategic cooperation framework agreement (“**Framework Agreement**”) with DOD Biotech Public Company Limited (“**DOD Biotech**”), a company incorporated in Thailand and is an independent third party, to cooperate in the development and commercialization of nutraceutical products (“**Nutraceutical Products**”) for a term of three years.

Major terms of the Framework Agreement are as follow:

- (i) DOD Biotech shall contribute its products formulation experiences and quality assurance capabilities in manufacturing premium quality Nutraceutical Products;
- (ii) the Group shall contribute its sales network in Asia and knowledge in the essence of functional herbal ingredients and traditional Chinese medicine in order to assess market potential of the Nutraceutical Products;
- (iii) the parties shall bring in their respective resources, expertise and experiences to support the research and development of the Nutraceutical Products;

- (iv) the parties shall jointly evaluate the commercial viability of the Nutraceutical Products in specific markets; and
- (v) for any of the Nutraceutical Products developed under the Framework Agreement, the parties shall cooperate to register such products under the Company's name.

Information about DOD Biotech

DOD Biotech is a Thailand-based company and the shares of which are listed on the Stock Exchange of Thailand. DOD Biotech is principally engaged in the manufacture of dietary supplement products with natural extracts as the main ingredients. DOD Biotech offers one-stop service, including production consultations, formula development, food serial number registration with the Food and Drug Administration (FDA), as well as product manufacturing.

Reasons and benefits of entering into the Framework Agreement

The Directors consider that by entering into the Framework Agreement with DOD Biotech, the parties could jointly develop, promote and commercialize Nutraceutical Products. The Group and DOD Biotech shall cooperate and make use of their respective commercially available resources and support from each other to launch products that meet consumer needs in specific markets. The transactions contemplated under the Framework Agreement, if materialized, would create new growth opportunities for the Group, which would in turn maximise the interests of the Company and its shareholders as a whole.

By Order of the Board
Ban Loong Holdings Limited
Liu Zhouyang
Executive Director & Deputy Chief Executive Officer

Hong Kong, 31 May 2022

As at the date of this announcement, the Board of the Company comprises:

Executive Directors:

Mr. Dong Ming (*Chairman*)
Mr. Chow Wang (*Deputy Chairman*)
Mr. Yin Pinyao
Mr. Wang Zhaoqing (*Chief Operating Officer*)
Mr. Liu Zhouyang (*Deputy Chief Executive Officer*)

Non-executive Director:

Mr. Qian Yinghui

Independent Non-executive Directors:

Mr. Jiang Zhi
Mr. Leung Ka Kui, Johnny
Ms. Wong Chui San, Susan